DMAC · NASDAQ
DiaMedica Therapeutics Inc.
$10.85 +0.06 (+0.60%)
Company overview
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is being evaluated in the Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes, as well as in Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. The company is also developing DM300, a preclinical-stage asset for the treatment of inflammatory diseases. DiaMedica Therapeutics Inc. was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $585M
- Employees
- 27
- Headquarters
- Minneapolis, MN
- Website
- diamedica.com
- CEO
- Dietrich John Pauls
- Listed
- August 3, 2012
- P/E
- -15.28
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- $0.00
- Operating income
- -$36.7M
- EBITDA
- -$36.7M
- Net income
- -$35.1M
- EPS
- -$0.71
- Total assets
- $53.1M
- Total debt
- $212,000
- Earnings yield
- -6.54%
DMAC
1D
NASDAQ
O10.15H11.00L10.15C10.79+0.79 (+7.85%)Vol365.22K
News